Prognostic and predictive values of mismatch repair deficiency in non-metastatic colorectal cancer

48Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

Abstract

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Universal MMR/MSI testing is standard of care for all patients with newly diagnosed CRC based on multi-society guidelines in the United States. Such testing is intended to identify patients with Lynch Syndrome due to a germline mutation in an MMR gene, but also detects those with sporadic dMMR/MSI-high CRCs. The prognostic utility of MMR/MSI status in non-metastatic colorectal cancer has been studied extensively, yet more limited data are available for its predictive utility. Results have not been entirely consistent due to potential stage-related differences and limited numbers of dMMR/MSI-H patients included in the studies. In this review, we summarize the current evidence for the prognostic and predictive value of dMMR/MSI-H in non-metastatic CRC, and discuss the use of this biomarker for patient management and treatment decisions in clinical practice.

Cite

CITATION STYLE

APA

Jin, Z., & Sinicrope, F. A. (2021). Prognostic and predictive values of mismatch repair deficiency in non-metastatic colorectal cancer. Cancers, 13(2), 1–16. https://doi.org/10.3390/cancers13020300

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free